BPC-157

BPC-157 (S0) — Body Protection Compound 157

A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.

100% 50% · t½ Time → Serum level
Molecular Weight
1419.53 Da
Half-Life
~5–30 min (animal data only)
Typical Dose
250–500 mcg
Cycle Length
4–12 weeks

Description

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. First described in the scientific literature in the 1990s by Dr. Predrag Sikiric and colleagues at the University of Zagreb, it has since become one of the most extensively studied research peptides, with over 100 published preclinical studies. Its healing properties span an extraordinary range of tissues including tendons, ligaments, muscles, bone, the gastrointestinal tract, peripheral nerves, and the central nervous system. Unlike many peptides that act on a single pathway, BPC-157 appears to be a pleiotropic healing agent that orchestrates multiple repair cascades simultaneously. It has demonstrated efficacy in models of inflammatory bowel disease, ulcers, fistulas, and even systemic organ damage from NSAIDs or alcohol.

Key Characteristics

Molecular FormulaC62H98N16O22
Molecular Weight1419.53 Da
Half-Life~5–30 min (animal data only)
Administration RoutesSubcutaneous injection, Intramuscular injection, Oral (for GI conditions)
Typical Dose250–500 mcg
FrequencyOnce or twice daily

Investigated Benefits

  • Accelerated tendon and ligament healing
  • GI tract repair and gastroprotection
  • Reduced inflammation
  • Muscle healing and recovery
  • Bone repair acceleration
  • Neuroprotective effects

* Benefits based on preclinical/animal research unless otherwise noted.

Regulatory Status

BPC-157 is not FDA-approved for any use and is not a lawful dietary ingredient. FDA placed it in Category 2 (significant safety risks) for compounding purposes in September 2023. A July 2026 FDA advisory committee voted to recommend several peptides for the 503A bulk-substances list over FDA staff’s objection, but that vote is non-binding and nothing has legally changed.